Biogen To Seek Re-examination Of Negative Opinion By EMA For Its 'aducanumab'

WESTON (dpa-AFX) - Biogen Inc. (BIIB), an American company focused on the therapies for the treatment of neurological diseases said it intends to seek re-examination of negative opinion adopted

Related Keywords

United States ,American ,Priya Singhal ,European Union ,European Medicines Agency ,Biogen Inc ,Committee For Medicinal Products Human Use ,Medicinal Products ,Human Use ,Marketing Authorization Application ,Global Safety ,Regulatory Sciences ,Biogen ,Eek ,Examination ,Negative ,Opinion ,Aducanumab ,